Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q2 2018 · 10-Q
Revenue$220.20M$220.20M+118.5% vs Q2 2017 Net Income$50.10M$50.10M+985.4% vs Q2 2017 EPS Diluted$0.98$0.98+790.9% vs Q2 2017 Gross Profit$66,800,000+685.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Operating Cash Flowderived$34,600,000−35.9% Free Cash Flowderived$21,000,000−53.0% Margins · derivedGross margin30.3%+21.9 pt vs Q2 2017
Operating margin30.3%+21.9 pt vs Q2 2017
Net margin22.8%+18.2 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 3, 2018 · 34 d after period end